Research Activity – Page 34 – Talk Bio

Actionable Insights Powered by AI

Evotec Announces 400 Job Cuts Amid Market Challenges

9 months ago talkbio0Tagged Challenge, Contract agreement, development aspects, Drug Discovery, Evotec, Manufacture, Market, restructuring

Evotec, job cuts, market challenges, restructuring, drug discovery, contract development, manufacturing

Novo Nordisk Pursues FDA Filing for Once-Weekly Insulin and Semaglutide Combo After Icodec Rejection

9 months ago talkbio0Tagged Clinical Research, COMBINE-1, File (record), Icodec, IcoSema, Insulin, Nordisk, once-weekly, regulatory approval, semaglutide, United States Food and Drug Administration

Novo Nordisk, insulin icodec, semaglutide, FDA filing, type 2 diabetes, once-weekly insulin, IcoSema, COMBINE-1 study, regulatory approval

Lilly Opens State-of-the-Art Research and Development Center in Boston

9 months ago talkbio0Tagged City of Boston, development aspects, East Coast, Eli Lilly, Incubators (device), research, Science of genetics

Lilly, Boston, research and development, genetics research, biotech incubator, East Coast hub

Syros Discontinues Mid-Stage Tamibarotene Program in Frontline Acute Myeloid Leukemia (AML)

9 months ago talkbio0Tagged Agonist, azacitidine, Clinical Trials, Futility Analysis, Leukemia, Myelocytic, Acute, RARα, SELECT-AML-1, Syros Pharmaceuticals, tamibarotene, venetoclax

Syros Pharmaceuticals, Tamibarotene, Acute Myeloid Leukemia (AML), Clinical Trial, SELECT-AML-1, Venetoclax, Azacitidine, RARα Agonist, Futility Analysis

Acelyrin Shifts Focus Amid Izokibep Setbacks, Lays Off Staff to Pursue Tepezza’s Market Share

9 months ago talkbio0Tagged Acelyrin, Clinical Trials, Izokibep, Market, setbacks, Strategy, Tepezza

Acelyrin, izokibep, clinical trial setbacks, layoffs, Tepezza, market strategy

Lykos Faces Significant Setbacks as FDA Rejects MDMA Therapy and Three Studies Are Retracted Due to Unethical Conduct

9 months ago talkbio0Tagged Clinical Research, Lykos ', Midomafetamine, Post-Traumatic Stress Disorder, psychedelic research, Rejection (Psychology), unethical conduct, United States Food and Drug Administration

Lykos Therapeutics, MDMA therapy, FDA rejection, study retractions, unethical conduct, PTSD treatment, psychedelic research

Halda Therapeutics Secures $126M to Advance ‘Hold and Kill’ Solid Tumor Drugs into Clinical Trials

9 months ago talkbio0Tagged Cancer Therapeutic Procedure, Clinical Trials, Halda, Malignant neoplasm of breast, Malignant neoplasm of prostate, RIPTAC, Series B extension financing, Solid Neoplasm

Halda Therapeutics, RIPTAC therapeutics, cancer treatment, solid tumors, prostate cancer, breast cancer, clinical trials, Series B extension financing

Exscientia Merges with Recursion to Form AI-Driven Drug Discovery Leader

9 months ago talkbio0Tagged AI, Artificial Intelligence, Drug Discovery, Exscientia, precision chemistry, Recursion, small molecule synthesis

Exscientia, Recursion, AI drug discovery, merger, precision chemistry, small molecule synthesis, biotech consolidation

Aldeyra’s Reproxalap Demonstrates Efficacy in Reducing Eye Discomfort in New Phase 3 Study

9 months ago talkbio0Tagged Discomfort, Dry Eye Syndromes, Eye, Phase 3 Clinical Trials, Rejection (Psychology), reproxalap, United States Food and Drug Administration

Aldeyra Therapeutics, Reproxalap, Phase 3 Study, Eye Discomfort, Dry Eye Disease, FDA Rejection

Analysts Uncover Nuances in Avidity’s DMD Data, Highlighting Promising Results

9 months ago talkbio0Tagged Avidity, Biosciences, Clinical Trials, Duchenne, Muscular Dystrophy, Muscular Dystrophy, Duchenne, RNA therapy

Avidity Biosciences, DMD, Duchenne Muscular Dystrophy, RNA therapy, phase 1/2 data, clinical trials, biotech, pharmaceuticals